Skip Navigation

Leidos Awarded $23.8 Million Contract to Support USAID Malaria Vaccine Development Program (MVDP)

6/2/2015

RESTON, VA, June 1, 2015  -- Leidos Inc. today announced that the U.S. Agency for International Development (USAID) has awarded Leidos a 5-year contract for providing scientific and management support for their Malaria Vaccine Development Program (MVDP). With the selection of Leidos to support MVDP’s continued effort to develop a highly effective malaria vaccine, USAID brings on a vaccine development contractor with deep roots in the malaria community. As prime contractor for the Malaria Vaccine Production and Support Services contract with the National Institute of Allergy and Infectious Diseases (NIAID), Leidos has proven to be a valuable partner for 14 years in delivering efficiency and innovation to the malaria vaccine community. Leidos teamed up with The Center for Vaccine Development (CVD) at the University of Maryland–Baltimore (UMB), and the Emory Vaccine Center (EVC) and Yerkes National Primate Research Center (Yerkes) of Emory University in Atlanta

Malaria continues to be a major public health problem in many parts of the developing world.  An estimated 655,000 persons died of malaria in 2010, with 86% of the victims being children under five years of age (WHO 2015). The current WHO target is reduction of malaria cases and mortality rates by >90% by the year 2030, and elimination of malaria in at least 35 countries over this same time period (WHO 2015).  Development of a malaria vaccine with 80% efficacy and duration of greater than four years is the goal for achieving this elimination strategy.  Therefore, Leidos will be instrumental in providing USAID MVDP the capability of integrating federal and non-profit funding resources with the large network of government and private labs, technology and experience to prototype and test new vaccines in the clinic and in the field. 

About Leidos

Leidos is a Fortune 500® scientific, engineering, and technology applications company that uses its deep domain knowledge to solve health problems of vital importance to the world. Since 2000, Leidos Life Sciences has held several large medical product development contracts with the Department of Defense (DoD), National Institutes of Health (NIH), Department of Homeland Security (DHS), and commercial sponsors.  Leidos Life Sciences plans and manages biological and small molecule development programs for various disease indications. Leidos provides services from initial concept to licensure, which include preclinical activities, GMP manufacturing, Investigational New Drug (IND) application preparation and submission, and clinical trial evaluation.